Paradigm BioCapital Advisors Takes 1.9M Share Stake in Tarsus Pharma

TL;DR

**Paradigm BioCapital just bought 1.9M shares of Tarsus, signaling a bullish institutional bet.**

AI Summary

Paradigm BioCapital Advisors LP, a Delaware-based investment firm, reported beneficial ownership of 1,927,506 shares of Tarsus Pharmaceuticals, Inc. common stock as of January 12, 2024. This represents a significant stake, giving Paradigm BioCapital Advisors LP sole voting power over these shares. This matters to Tarsus shareholders because a large institutional investor taking a substantial position can signal confidence in the company's future, potentially influencing stock price and future strategic decisions.

Why It Matters

A major institutional investor, Paradigm BioCapital Advisors LP, has acquired a significant stake in Tarsus Pharmaceuticals, indicating potential long-term confidence in the company's prospects.

Risk Assessment

Risk Level: low — This filing indicates an institutional investor has taken a significant position, which is generally seen as a positive signal and reduces perceived risk.

Analyst Insight

A smart investor would view this as a positive signal, indicating institutional confidence in Tarsus Pharmaceuticals, and might consider further research into the company's fundamentals and future prospects.

Key Numbers

• 1,927,506 — Shares Beneficially Owned (Represents the total number of Tarsus Pharmaceuticals shares Paradigm BioCapital Advisors LP has sole voting power over.)
• January 12, 2024 — Date of Event (The date that triggered the requirement for this SC 13G filing.)
• 87650L103 — CUSIP Number (Unique identifier for Tarsus Pharmaceuticals, Inc. Common Stock.)

Key Players & Entities

• Paradigm BioCapital Advisors LP (company) — reporting person and beneficial owner of shares
• Tarsus Pharmaceuticals, Inc. (company) — the subject company whose shares are being reported
• Senai Asefaw, M.D. (person) — group member associated with Paradigm BioCapital
• Delaware (company) — place of organization for Paradigm BioCapital Advisors LP

Forward-Looking Statements

• Paradigm BioCapital Advisors LP will maintain or increase its stake in Tarsus Pharmaceuticals, Inc. over the next 6-12 months. (Paradigm BioCapital Advisors LP) — medium confidence, target: January 2025

FAQ

Key Financial Figures

• $0.0001 — Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class o

Filing Documents

• tm243654d1_sc13g.htm (SC 13G) — 64KB
• tm243654d1_ex1.htm (EX-99.1) — 4KB
• 0001104659-24-005611.txt ( ) — 70KB

If this statement is filed pursuant to 240.13d-1(b) or

Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) ¨ An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) ¨ An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); (g) ¨ A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J); (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: Page 6 of 10 Pages

Ownership

Item 4. Ownership. See Items 5-9 and 11 on the cover page for each Reporting Person, and Item 2, which information is given as of the close of business on January 22, 2024, the date of filing of this Schedule 13G. As of the close of business on the Event Date of January 12, 2024, the Reporting Persons collectively beneficially owned 1,694,393 shares of Common Stock (1,444,256 of which was held by the Fund and 250,137 of which was held by the Account), representing 5.1% of all of the outstanding shares of Common Stock. The percentages of beneficial ownership contained herein are based on 33,104,612 shares of Common Stock outstanding as of December 27, 2023, as reported in a Form 144 filed with the SEC on December 27, 2023.

Ownership of Five Percent or Less of a Class

Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:

Ownership of More than Five Percent on Behalf of Another

Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable.

Identification and Classification of the Subsidiary Which

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not applicable.

Identification and Classification of Members of the Group

Item 8. Identification and Classification of Members of the Group. Not applicable. Page 7 of 10 Pages

Notice of Dissolution of Group

Item 9. Notice of Dissolution of Group. Not applicable.

Certification

Item 10. Certification. (a) Not applicable. (b) Not applicable. (c) By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11. Page 8 of 10 Pages SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: January 22, 2024 Paradigm BioCapital Advisors LP Paradigm BioCapital Advisors GP LLC Paradigm BioCapital International Fund Ltd. By: /s/ David K. Kim Name: David K. Kim Title: Authorized Signatory /s/ Senai Asefaw, M.D. Senai Asefaw, M.D. Page 9 of 10 Pages EXHIBIT INDEX Exhibit No. Document 1 Joint Filing Agreement Page 10 of 10 Pages

View Full Filing

View this SC 13G filing on SEC EDGAR